Abnormal activity of the epidermal growth factor receptor (EGFR) is associated with various cancer-related processes and motivates the search for strategies that can selectively block EGFR signalling. In this study, functional knockdown of EGFR was achieved through expression of an affibody construct, (ZEGFR:1907)(2-)KDEL, with high affinity for EGFR and extended with the amino acids KDEL to make it resident in the secretory compartments. Expression of (ZEGFR:1907)(2-)KDEL resulted in 80% reduction ofthe cell surface level of EGFR, and fluorescent staining for EGFR and the (ZEGFR:1907)(2-)KDEL construct showed overlapping intracellular localisation. Immunocapture of EGFR from cell lysates showed that an intracellular complex between EGFR and the affibody construct had been formed, further indicating aspecific interaction between the affibody construct and EGFR. Surface depletion of EGFR led to a dramatic decrease in the amount of kinase domain phosphorylated EGFR, coincident with a significant decrease in the proliferation rate.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.nbt.2009.02.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A novel format of TNF-α binding affibody molecule ameliorate coronary artery endothelial injury in a mouse model of Kawasaki disease.
Int J Biol Macromol
November 2024
Department of Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China; Key Laboratory of Structural Malformations in Children of Zhejiang Province, 325027 Wenzhou, Zhejiang, China; Children's Heart Center, Institute of Cardiovascular Development and Translational Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, China. Electronic address:
Article Synopsis
- Kawasaki disease (KD) is an autoimmune condition that affects blood vessels and can lead to heart issues, prompting research into new treatment methods like anti-TNFα monoclonal antibodies.
- A novel therapeutic agent, an affibody designed to target TNF-α, was developed and showed strong binding and neutralizing effects against TNF-α, differentiating it from traditional mAbs.
- The engineered affibody, known as ZTAT, demonstrated effectiveness in treating KD-related endothelial injury, showcasing potential as a cost-effective therapeutic option with a longer serum half-life.
An anti-sortilin affibody-peptide fusion inhibits sortilin-mediated progranulin degradation.
Front Immunol
August 2024
Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden.
Heterozygous loss-of-function mutations in the gene are a common cause of frontotemporal dementia. Such mutations lead to decreased plasma and cerebrospinal fluid levels of progranulin (PGRN), a neurotrophic factor with lysosomal functions. Sortilin is a negative regulator of extracellular PGRN levels and has shown promise as a therapeutic target for frontotemporal dementia, enabling increased extracellular PGRN levels through inhibition of sortilin-mediated PGRN degradation.
View Article and Find Full Text PDFAffimer reagents enable targeted delivery of therapeutic agents and RNA via virus-like particles.
iScience
August 2024
School of Molecular and Cellular Biology, University of Leeds, Leeds, UK.
Monoclonal antibodies have revolutionized therapies, but non-immunoglobulin scaffolds are becoming compelling alternatives owing to their adaptability. Their ability to be labeled with imaging or cytotoxic compounds and to create multimeric proteins is an attractive strategy for therapeutics. Focusing on HER2, a frequently overexpressed receptor in breast cancer, this study addresses some limitations of conventional targeting moieties by harnessing the potential of these scaffolds.
View Article and Find Full Text PDFEvaluation of a novel Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile.
Eur J Nucl Med Mol Imaging
November 2024
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, 751 85, Sweden.
Purpose: Fusion of Affibody molecules with an albumin-binding domain (ABD) provides targeting agents, which are suitable for radionuclide therapy. To facilitate clinical translation, the low immunogenic potential of such constructs with targeting properties conserved is required.
Methods: The HER2-targeting Affibody molecule ZHER2:2891 was fused with a deimmunized ABD variant and DOTA was conjugated to a unique C-terminal cysteine.
Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.
J Control Release
June 2024
Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden. Electronic address:
Article Synopsis
- Developing protein therapeutics requires optimizing their pharmacokinetic and pharmacodynamic properties, particularly to prolong their half-lives in the body.
- A study compared various half-life extension technologies (PAS polypeptides, XTEN polypeptides, and an albumin binding domain) using an HER2 affibody-drug conjugate, revealing that while these extensions lowered HER2 affinity slightly, they maintained cytotoxic effectiveness.
- The results indicated that the ABD-enhanced construct had the highest tumor uptake and the best overall performance, despite not having the longest half-life compared to others tested.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!